Mazanti-Andersen

Mazanti-Andersen advised Hemab on the deal. The Denmark and US-based biotech company Hemab raised USD 135 million in oversubscribed series B financing. Access Biotechnology led the round...

Mazanti-Andersen advised Upfin on the deal. Upfin is a new venture capital fund dedicated to supporting the Nordic fintech community. Its first fund has raised DKK...

Moalem Weitemeyer assisted Monterro on the deal. Mazanti-Andersen advised TimeXtender. Monterro announced the acquisition of the Danish software developer, TimeXtender. TimeXtender is a leading data estate builder...

Mazanti-Andersen advised Jeito Capital on the deal. The Danish biotech company NMD Pharma A/S has raised EUR 35 million in a financing round led by new...

Moalem Weitemeyer assisted Pento in the transaction. Mazanti advised Avid Ventures and General Catalyst. Danish startup Pento ApS closed its USDm 35 Series B round which was...

Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction. Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of...

Moalem Weitemeyer assisted Scrive on the deal. Mazanti-Andersen advised esignatur. Scrive, a portfolio company of Vitruvian Partners, announced the acquisition of esignatur. Scrive and esignatur both specialize...

Lundgrens and Vinge assisted Advania Danmark A/S on the deal. Mazanti advised the sellers of Genia ApS. Advania Danmark A/S announced the acquisition of Genia ApS. Advania...

Shearman & Sterling advised the underwriters in the offering. Mazanti advised Y-mAbs Therapeutics.r Y-mAbs Therapeutics, Inc. executed its 2,804,878 shares of common stock at a public offering...

Kromann Reumert and Sidley Austin LLP advised KKR on its purchase. Mazanti-Andersen advises the sellers. Nordic Bioscience A/S, a Danish company and world leader in biomarker...

Accura was local counsel for Oppenheimer & Co. who was lead underwriter in connection with the ADS listing. Mazanti advised Evaxion Biotech. The Danish biotech company...